CTOs on the Move

Amplyx Pharmaceuticals

www.amplyx.com

 
Amplyx Pharmaceuticals, Inc. is a preclinical stage company focusing on the development of small molecule drugs with enhanced efficacy and lower toxicity. Amplyx employs a platform approach to improve small molecule drugs by the addition of a second small molecule to an existing drug. The resulting, new therapeutic creates a more targeted molecule with the goal of improving treatment outcomes and improving compliance with treatment regimens. Our initial development areas are in oncology and infectious disease.
  • Number of Employees: 0-25
  • Annual Revenue: $10-50 Million
  • www.amplyx.com
  • 3210 Merryfield Row
    San Diego, CA USA 92121-1126
  • Phone: 415.578.3263

Executives

Name Title Contact Details

Funding

Amplyx Pharmaceuticals raised $40.5M on 11/11/2015
Amplyx Pharmaceuticals raised $53M on 05/19/2020

Similar Companies

The eNose Company

We want to produce and market early-warning systems for specific smells related to diseases, safety and well-being. We want to enhance the time and cost efficiency in diagnosing diseases through breath analysis and Microbe detection.

Astellas

Astellas Pharma US, Inc., a U.S. affiliate of Tokyo-based Astellas Pharma Inc., is a pharmaceutical company dedicated to changing tomorrow by improving the health of people around the world through innovative and reliable pharmaceutical products. In 2005, Astellas was formed by blending the talents, resources and passions of two highly successful firms - Yamanouchi and Fujisawa. Astellas aims to maintain and strengthen our position as the global leader in transplantation and urology areas, and going forward we are working to establish our position as a global category leader in oncology. At all levels throughout the company our people are committed to the opportunity to positively affect and improve patient lives while remaining socially responsible to our community and those with whom we work and collaborate.

Innovacon

Innovacon, Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Amolyt Pharma

Amolyt Pharma is building on its team`s established expertise in therapeutic peptides development to deliver life-changing treatments to patients suffering from rare endocrine and metabolic diseases. Amolyt Pharma`s programs include AZP-3601, a parathyroid hormone analog, for the potential treatment of hypoparathyroidism and AZP-3404, a peptide with a new and unique mechanism of action, that may restore fat and glucose metabolism. The collaborative Amolyt Pharma team is well-equipped for upcoming milestones and for the adoption of additional programs as made possible by its global network in the field of endocrinology and with support from a strong syndicate of international investors.

Bridgeway

Bridgeway provides services for individuals with developmental disabilites, families